Journal
PHARMACEUTICALS
Volume 6, Issue 10, Pages 1304-1321Publisher
MDPI
DOI: 10.3390/ph6101304
Keywords
Alzheimer's; repositioning; treatment; drug
Categories
Funding
- National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre
- Dementia Unit at South London and Maudsley NHS Foundation Trust
- Institute of Psychiatry, King's College London
Ask authors/readers for more resources
Alzheimer's Disease (AD) is the most common cause of dementia, affecting approximately two thirds of the 35 million people worldwide with the condition. Despite this, effective treatments are lacking, and there are no drugs that elicit disease modifying effects to improve outcome. There is an urgent need to develop and evaluate more effective pharmacological treatments. Drug repositioning offers an exciting opportunity to repurpose existing licensed treatments for use in AD, with the benefit of providing a far more rapid route to the clinic than through novel drug discovery approaches. This review outlines the current most promising candidates for repositioning in AD, their supporting evidence and their progress through trials to date. Furthermore, it begins to explore the potential of new transcriptomic and microarray techniques to consider the future of drug repositioning as a viable approach to drug discovery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available